TLRs promote host defense through recognizing pathogenassociated molecular patterns released by microorganisms (1). TLR activation initiates potent inflammatory cytokine production and dendritic cell activation that drive the expansion and differentiation of Ag-specific T cells. These observations have led to the clinical use of TLR agonists to promote antitumor responses. These include the use of the TLR7 agonist imiquimod and live preparations of Mycobacterium bovis bacillus of the Calmette-Gue´rin strain to treat superficial skin and bladder carcinomas, respectively (2, 3). However, TLR agonist therapy has been largely restricted to mucosal lesions because of potential systemic toxicity (4). Although most studies have

Naive CD4+ T cells carrying a TLR2 agonist overcome TGF-b–mediated tumor immune evasion / Ibrahim, Mohsen; Scozzi, Davide; Toth, Kelsey A.; Ponti, Donatella; Kreisel, Daniel; Menna, Cecilia; De Falco, Elena; Antonio, D’andrilli; Rendina, Erino A.; Calogero, Antonella; Krupnick, Alexander S.; Gelman, Andrew E.. - In: JOURNAL OF IMMUNOLOGY. - ISSN 0022-1767. - ELETTRONICO. - 200:2(2018), pp. 847-856. [10.4049/jimmunol.1700396]

Naive CD4+ T cells carrying a TLR2 agonist overcome TGF-b–mediated tumor immune evasion

Mohsen Ibrahim;Davide Scozzi;Donatella Ponti;Cecilia Menna;Elena De Falco;Antonio D’andrilli;Erino A. Rendina;Antonella Calogero;
2018

Abstract

TLRs promote host defense through recognizing pathogenassociated molecular patterns released by microorganisms (1). TLR activation initiates potent inflammatory cytokine production and dendritic cell activation that drive the expansion and differentiation of Ag-specific T cells. These observations have led to the clinical use of TLR agonists to promote antitumor responses. These include the use of the TLR7 agonist imiquimod and live preparations of Mycobacterium bovis bacillus of the Calmette-Gue´rin strain to treat superficial skin and bladder carcinomas, respectively (2, 3). However, TLR agonist therapy has been largely restricted to mucosal lesions because of potential systemic toxicity (4). Although most studies have
2018
T Cd4
01 Pubblicazione su rivista::01a Articolo in rivista
Naive CD4+ T cells carrying a TLR2 agonist overcome TGF-b–mediated tumor immune evasion / Ibrahim, Mohsen; Scozzi, Davide; Toth, Kelsey A.; Ponti, Donatella; Kreisel, Daniel; Menna, Cecilia; De Falco, Elena; Antonio, D’andrilli; Rendina, Erino A.; Calogero, Antonella; Krupnick, Alexander S.; Gelman, Andrew E.. - In: JOURNAL OF IMMUNOLOGY. - ISSN 0022-1767. - ELETTRONICO. - 200:2(2018), pp. 847-856. [10.4049/jimmunol.1700396]
File allegati a questo prodotto
File Dimensione Formato  
Ibrahim_Naive-CD4+_2017.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 2.36 MB
Formato Adobe PDF
2.36 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1017800
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 8
social impact